Baseline characteristics of patients who received teclistamab
| Characteristic, N = 384 (100%) . | RI group n = 81 . | No RI group n = 303 . | P value . |
|---|---|---|---|
| Age, median (IQR), y | 71 (63.9-76) | 67 (60.2-72.1) | .002 |
| Female sex, n (%) | 45 (56) | 136 (45) | .11 |
| Race, n (%) | |||
| White | 53 (65) | 201 (66) | .83 |
| Black | 20 (25) | 67 (22) | |
| Other | 8 (10) | 35 (12) | |
| Ethnicity (n = 370), n (%) | n = 76 | n = 294 | |
| Hispanic | 4 (5) | 27 (9) | .21 |
| Non-Hispanic | 72 (95) | 267 (91) | |
| Light chain type, n (%) | |||
| Kappa | 46 (57) | 194 (64) | .47 |
| Lambda | 35 (43) | 106 (35) | |
| Biclonal | 0 (0) | 1 (0.3) | |
| Nonsecretory | 0 (0) | 2 (0.6) | |
| ECOG PS (n = 375), n (%) | n = 80 | n = 295 | |
| 0-1 | 58 (72) | 221 (75) | .76 |
| ≥2 | 22 (28) | 74 (25) | |
| Cytogenetic risk, n (%) | |||
| Standard risk | 33 (41) | 139 (46) | .48 |
| High risk | 48 (59) | 164 (54) | |
| Double-hit MM | 16 (20) | 65 (21.5) | .85 |
| EMD, n (%) | 18 (22) | 82 (27) | .45 |
| Triple-class refractory, n (%) | 64 (79) | 257 (85) | .27 |
| Penta-class refractory, n (%) | 31 (38) | 113 (37) | .97 |
| No. of prior lines, median (IQR) (n = 374) | 7 (5-9) | 6 (5-8) | .04 |
| Previous autologous SCT, n (%) | 49 (60.5) | 205 (70) | .28 |
| Previous BCMA-directed therapy, n (%) | 37 (46) | 155 (51) | .45 |
| Cytopenias at baseline, n (%) | |||
| Any-grade neutropenia | 16/80 (20) | 76/298 (26) | .3 |
| Grade ≥3 neutropenia | 4/80 (5) | 22/298 (7.4) | .5 |
| Any-grade anemia | 74/80 (93) | 222/299 (74) | <.001 |
| Grade ≥3 anemia | 24/80 (30) | 45/299 (15) | .002 |
| Any-grade thrombocytopenia | 58/80 (73) | 165/299 (55) | .005 |
| Grade ≥3 thrombocytopenia | 20/80 (25) | 46/299 (15) | .044 |
| Characteristic, N = 384 (100%) . | RI group n = 81 . | No RI group n = 303 . | P value . |
|---|---|---|---|
| Age, median (IQR), y | 71 (63.9-76) | 67 (60.2-72.1) | .002 |
| Female sex, n (%) | 45 (56) | 136 (45) | .11 |
| Race, n (%) | |||
| White | 53 (65) | 201 (66) | .83 |
| Black | 20 (25) | 67 (22) | |
| Other | 8 (10) | 35 (12) | |
| Ethnicity (n = 370), n (%) | n = 76 | n = 294 | |
| Hispanic | 4 (5) | 27 (9) | .21 |
| Non-Hispanic | 72 (95) | 267 (91) | |
| Light chain type, n (%) | |||
| Kappa | 46 (57) | 194 (64) | .47 |
| Lambda | 35 (43) | 106 (35) | |
| Biclonal | 0 (0) | 1 (0.3) | |
| Nonsecretory | 0 (0) | 2 (0.6) | |
| ECOG PS (n = 375), n (%) | n = 80 | n = 295 | |
| 0-1 | 58 (72) | 221 (75) | .76 |
| ≥2 | 22 (28) | 74 (25) | |
| Cytogenetic risk, n (%) | |||
| Standard risk | 33 (41) | 139 (46) | .48 |
| High risk | 48 (59) | 164 (54) | |
| Double-hit MM | 16 (20) | 65 (21.5) | .85 |
| EMD, n (%) | 18 (22) | 82 (27) | .45 |
| Triple-class refractory, n (%) | 64 (79) | 257 (85) | .27 |
| Penta-class refractory, n (%) | 31 (38) | 113 (37) | .97 |
| No. of prior lines, median (IQR) (n = 374) | 7 (5-9) | 6 (5-8) | .04 |
| Previous autologous SCT, n (%) | 49 (60.5) | 205 (70) | .28 |
| Previous BCMA-directed therapy, n (%) | 37 (46) | 155 (51) | .45 |
| Cytopenias at baseline, n (%) | |||
| Any-grade neutropenia | 16/80 (20) | 76/298 (26) | .3 |
| Grade ≥3 neutropenia | 4/80 (5) | 22/298 (7.4) | .5 |
| Any-grade anemia | 74/80 (93) | 222/299 (74) | <.001 |
| Grade ≥3 anemia | 24/80 (30) | 45/299 (15) | .002 |
| Any-grade thrombocytopenia | 58/80 (73) | 165/299 (55) | .005 |
| Grade ≥3 thrombocytopenia | 20/80 (25) | 46/299 (15) | .044 |
Triple-class refractory is defined as refractory to ≥1 immunomodulatory drug, ≥1 proteasome inhibitor, and ≥1 anti-CD38 monoclonal antibody. Penta-class refractory is defined as refractory to ≥2 immunomodulatory drugs, ≥2 proteasome inhibitors, and ≥1 anti-CD38 monoclonal antibody.
BCMA, B-cell maturation antigen; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; RI, renal impairment; SCT, stem cell transplantation.